This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $459,131 to The Ohio State University to conduct research focused on the essential functions of the mitochondrion in malaria parasites. The goal is to expand the druggable parasite proteome and identify new therapeutic targets within the parasite mitochondrion, which is a promising source of drug targets due to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $147,656 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on the role of transmembrane proteins for Plasmodium cell division. The research aims to decipher the precise location of transmembrane proteins within the Plasmodium basal complex, a critical structure...
This $1,373,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to optimize the structural features of the anti-malarial compound ELQ-596. The goal is to develop a next generation of ELQ compounds for once-monthly oral prophylaxis against malaria in humans. The research team, which includes experts in medicinal chemistry, malaria, molecular parasitology, biochemistry, structural biology,...
This $924,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research at Tufts University School of Medicine to study mechanisms of erythrocyte adhesion in Plasmodium falciparum malaria, a leading cause of mortality worldwide. The key objectives are to: 1) Elucidate the mechanism of knob self-assembly on the surface of infected red blood cells, which...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $375,000.00 to the University of South Florida to conduct research on the functions of messenger ribonucleoproteins (mRNPs) in regulating RNA metabolism in the malaria parasite Plasmodium falciparum. The key objectives of this 5-year project are to: 1) identify molecular markers and characterize the protein and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,056 in funding to The Washington University to conduct research on heme homeostasis in the malaria parasite Plasmodium falciparum. The research aims to identify parasite proteins involved in maintaining heme levels and explore their potential as novel antimalarial drug targets. The award period runs from July...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to establish continuous, high-yield culture systems for the malaria parasite Plasmodium vivax (P. vivax) and use this system to study the triggers of gametocytogenesis (sexual stage development) in vitro. The total funding amount is $392,710.00, awarded to the University of Georgia Research Foundation, Inc. (UGA Research...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU). The funding supports the optimization of a next-generation antimalarial drug candidate, ELQ-596, to enable once-monthly oral prophylaxis in humans. Specifically, the research aims to enhance the structural features of ELQ-596 to improve its intrinsic anti-plasmodial activity,...
This federal Project Grant award of $791,864, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify the molecular factors that control chromatin organization and gene regulation in the human malaria parasite Plasmodium falciparum. The key objectives of the project are to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...
The federal Project Grant award F31AI174772 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding of $206,116 will support research at Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The research aims to further optimize a lead...
PROTON PUMPING AND ENERGY METABOLISM OF THE RING STAGE MALARIA PARASITES - MALARIA REMAINS A MAJOR GLOBAL HEALTH BURDEN, AFFECTING 40% OF THE WORLD'S POPULATION. IN 2021, THERE WERE 247 MILLION REPORTED CASES, RESULTING IN OVER 619,000 DEATHS. THE DISEASE IS CAUSED BY REPETITIVE GROWTH OF THE PROTOZOAN PARASITES KNOWN AS PLASMODIUM SPP. INSIDE RED BLOOD CELLS (RBCS), LEADING TO RBC LYSIS. AMONG THE FIVE MALARIA SPECIES INFECTING HUMANS, PLASMODIUM FALCIPARUM IS THE MOST LETHAL, RESPONSIBLE FOR MORE THAN 80% OF THE DISEASE'S MORBIDITY AND MORTALITY. THIS PARASITE UNDERGOES ASEXUAL REPRODUCTION WITHIN RBCS OVER ITS 48-HOUR LIFECYCLE, WHICH CONSISTS OF THREE MAJOR STAGES: THE RING STAGE (~ 20 HOURS), THE TROPHOZOITE STAGE (~ 16 HOURS) AND THE SCHIZONT STAGE (~12 HOURS). DURING THE RING STAGE, INFECTED RBCS (IRBCS) HAVE A SMOOTH SURFACE LIKE UNINFECTED RBCS, ENABLING THEM TO EVADE CLEARANCE BY THE SPLEEN AND CIRCULATE IN THE PERIPHERAL BLOODSTREAM. THIS STAGE IS METABOLICALLY QUIESCENT AND CHALLENGING TO TARGET WITH AVAILABLE ANTIMALARIALS, AS MOST OF THESE DRUGS ARE NOT HIGHLY EFFECTIVE AGAINST THE SLOW-GROWING PARASITE. FURTHERMORE, THE RING STAGE CAN ENTER A DORMANT STATE AFTER DRUG TREATMENT, CONTRIBUTING TO DRUG RESISTANCE. THEREFORE, THERE IS AN URGENT NEED FOR A BETTER UNDERSTANDING OF THE FUNDAMENTAL BIOLOGY OF RING STAGE MALARIA PARASITES. OUR LABORATORY HAS MADE A SIGNIFICANT DISCOVERY BY REVEALING THAT THE METABOLICALLY INACTIVE RING STAGE PARASITE EMPLOYS AN ANCIENT PYROPHOSPHATE-DRIVEN PROTON PUMP TO SURVIVE FOR 20 HOURS INSIDE THE RBC FOLLOWING THE TIME OF INVASION. THIS ATP-INDEPENDENT PROTON PUMP IS KNOWN AS PFVP1 (PLASMODIUM FALCIPARUM VACUOLAR PYROPHOSPHATASE 1), AND IT DERIVES ENERGY FROM THE HYDROLYSIS OF PYROPHOSPHATE (PPI), A METABOLIC BY-PRODUCT GENERATED DURING SYNTHESIS OF DNA, RNA, AND PROTEIN. BASED ON THESE OBSERVATIONS, WE HYPOTHESIZE THAT THE RING-STAGE P. FALCIPARUM RELIES ON AN ATP-INDEPENDENT MECHANISM FOR PROTON EXPORTING AND ESTABLISHING PLASMA MEMBRANE POTENTIAL, IDENTIFYING A DISTINCTIVE VULNERABILITY IN THIS CHALLENGING STAGE OF THE ASEXUAL LIFECYCLE. TO TEST THIS HYPOTHESIS, WE OUTLINE TWO SPECIFIC AIMS. AIM I. INVESTIGATE THE IMPACT OF PFVP1'S LOOP SEQUENCES ON ITS PROTON PUMPING FUNCTIONALITY. AIM II. EXAMINE POLYPHOSPHATE METABOLISM AND PPI METABOLISM TO UNDERSTAND THE ENERGY SOURCE FOR PFVP1. THE OUTCOMES OF THIS RESEARCH PROPOSAL WILL PROVIDE INSIGHTS INTO HOW THE METABOLICALLY QUIESCENT RING STAGE PARASITE SURVIVES WITHIN THE RBC FOR NEARLY A DAY FOLLOWING INVASION. GIVEN THE ESSENTIAL NATURE OF PFVP1 AND ITS ABSENCE IN HUMANS, PFVP1 EMERGES AS AN IDEAL TARGET FOR COMBATING THE RING STAGE PARASITES. INHIBITING THIS LESS ACTIVE STAGE IS OF UTMOST IMPORTANCE TO ADVANCE MALARIA CONTROL AND ERADICATION EFFORTS.